OA13170A - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. - Google Patents
Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. Download PDFInfo
- Publication number
- OA13170A OA13170A OA1200500329A OA1200500329A OA13170A OA 13170 A OA13170 A OA 13170A OA 1200500329 A OA1200500329 A OA 1200500329A OA 1200500329 A OA1200500329 A OA 1200500329A OA 13170 A OA13170 A OA 13170A
- Authority
- OA
- OAPI
- Prior art keywords
- formula
- compound
- group
- compounds
- pyrazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47266103P | 2003-05-22 | 2003-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA13170A true OA13170A (en) | 2006-12-13 |
Family
ID=33476970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200500329A OA13170A (en) | 2003-05-22 | 2004-04-27 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. |
Country Status (36)
Country | Link |
---|---|
US (8) | US7482354B2 (he) |
EP (1) | EP1636236B1 (he) |
JP (1) | JP5043432B2 (he) |
KR (1) | KR101084871B1 (he) |
CN (2) | CN102079746A (he) |
AP (1) | AP2064A (he) |
AR (2) | AR044543A1 (he) |
AU (1) | AU2004240772B2 (he) |
BR (2) | BRPI0410563B8 (he) |
CA (1) | CA2526578C (he) |
CO (1) | CO5721006A2 (he) |
CR (1) | CR8102A (he) |
CY (1) | CY1114708T1 (he) |
DK (1) | DK1636236T3 (he) |
EA (1) | EA010904B1 (he) |
EC (1) | ECSP056194A (he) |
ES (1) | ES2436524T3 (he) |
GE (1) | GEP20094664B (he) |
HR (1) | HRP20050967B8 (he) |
IL (1) | IL172046A (he) |
IS (1) | IS2939B (he) |
ME (1) | ME00142B (he) |
MX (1) | MXPA05012573A (he) |
MY (1) | MY142019A (he) |
NO (1) | NO334992B1 (he) |
NZ (1) | NZ543661A (he) |
OA (1) | OA13170A (he) |
PL (1) | PL1636236T3 (he) |
PT (1) | PT1636236E (he) |
RS (2) | RS20050944A (he) |
SI (1) | SI1636236T1 (he) |
TN (1) | TNSN05298A1 (he) |
TW (1) | TWI349672B (he) |
UA (1) | UA80763C2 (he) |
WO (1) | WO2004104007A1 (he) |
ZA (1) | ZA200509486B (he) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2436524T3 (es) * | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
ITMI20041033A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
AU2007213791A1 (en) * | 2006-02-10 | 2007-08-16 | Nerviano Medical Sciences S.R.L. | Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic |
EP2026800A1 (en) * | 2006-05-09 | 2009-02-25 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
US20080015193A1 (en) * | 2006-06-20 | 2008-01-17 | Mendoza Jose S | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof |
US7517882B2 (en) | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
JP5498796B2 (ja) * | 2006-12-21 | 2014-05-21 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ピラゾロ−キナゾリン誘導体、これらの調製方法及びキナーゼ阻害剤としてのこれらの使用 |
ZA200904912B (en) * | 2006-12-21 | 2010-09-29 | Nerviano Medical Sciences Srl | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
CA2703489A1 (en) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
EP2231656A1 (en) | 2007-12-19 | 2010-09-29 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
US8389533B2 (en) * | 2008-04-07 | 2013-03-05 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
TWI426074B (zh) * | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | 5-(2-胺基-嘧啶-4-基)-2-芳基-1h-吡咯-3-羧醯胺之製造方法 |
AU2009264431B2 (en) * | 2008-06-26 | 2013-11-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazolines |
ES2964764T3 (es) * | 2008-07-29 | 2024-04-09 | Nerviano Medical Sciences Srl | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino |
ES2532732T3 (es) * | 2008-07-29 | 2015-03-31 | Nerviano Medical Sciences S.R.L. | Uso de un inhibidor de CDK para el tratamiento del glioma |
WO2010043676A1 (en) * | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
EP2376084B1 (en) | 2008-11-24 | 2013-07-17 | Nerviano Medical Sciences S.r.l. | CDK inhibitor for the treatment of mesothelioma |
IT1395724B1 (it) * | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
JP5650193B2 (ja) * | 2009-03-20 | 2015-01-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 胸腺腫の治療のためのキナーゼ阻害剤の使用 |
WO2010122091A1 (en) * | 2009-04-22 | 2010-10-28 | Boehringer Ingelheim International Gmbh | Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer |
JP5801285B2 (ja) * | 2009-04-29 | 2015-10-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Cdk阻害物質の塩 |
AR076784A1 (es) | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
CN103626777B (zh) * | 2009-07-29 | 2015-10-21 | 内尔维阿诺医学科学有限公司 | Plk抑制剂的盐类 |
JP2013518129A (ja) * | 2010-01-28 | 2013-05-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | プロテアソーム活性を向上させるための組成物および方法 |
US8735386B2 (en) | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
JP5997143B2 (ja) * | 2010-07-30 | 2016-09-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン |
CN103124723A (zh) | 2010-09-23 | 2013-05-29 | 先正达参股股份有限公司 | 新颖的杀微生物剂 |
KR101929593B1 (ko) * | 2010-10-25 | 2018-12-14 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
BR112013008527A2 (pt) * | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
JP5925809B2 (ja) * | 2011-01-26 | 2016-05-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
EP2668188B1 (en) * | 2011-01-26 | 2016-05-18 | Nerviano Medical Sciences S.r.l. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
WO2012117021A2 (en) | 2011-03-03 | 2012-09-07 | Syngenta Participations Ag | Novel microbiocidal oxime ethers |
ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
US9556166B2 (en) | 2011-05-12 | 2017-01-31 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
WO2013092460A1 (en) | 2011-12-20 | 2013-06-27 | Syngenta Participations Ag | Cyclic bisoxime microbicides |
TW201343648A (zh) * | 2012-01-23 | 2013-11-01 | Boehringer Ingelheim Int | 作為igf-1r/ir抑制劑之新5,8-二氫-6h-吡唑并[3,4-h]喹唑啉 |
EP2641901A1 (en) | 2012-03-22 | 2013-09-25 | Syngenta Participations AG. | Novel microbiocides |
ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
CN105407723A (zh) | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
PL2968290T3 (pl) | 2013-03-15 | 2020-04-30 | G1 Therapeutics, Inc. | Przejściowa ochrona prawidłowych komórek podczas chemioterapii |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
HUE043108T2 (hu) | 2014-04-07 | 2019-07-29 | Netherlands Translational Res Center B V | (5,6-dihidro)pirimido[4,5-e]indolizinek |
WO2015161288A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
WO2015181737A1 (en) | 2014-05-28 | 2015-12-03 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
BR112018000841A8 (pt) | 2015-07-17 | 2022-11-22 | Pasteur Institut | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites |
CA3030054A1 (en) | 2016-07-15 | 2018-01-18 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair |
EP3505519B1 (en) * | 2016-11-11 | 2022-01-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines |
CN110997678B (zh) * | 2017-07-11 | 2023-02-21 | 内尔维亚诺医疗科学公司 | 作为胆碱激酶抑制剂的吡唑并喹唑啉衍生物 |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
US11319323B2 (en) | 2017-08-11 | 2022-05-03 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors |
WO2021043190A1 (zh) * | 2019-09-05 | 2021-03-11 | 成都赛诺希亚生物科技有限公司 | 异噁唑并[5,4-h]喹唑啉类化合物作为蛋白激酶抑制剂 |
WO2021084541A1 (en) * | 2019-10-31 | 2021-05-06 | Sol-Gel Technologies Ltd. | Treatment of hair loss disorders with a topical egfr inhibitor |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN114685520A (zh) * | 2020-12-25 | 2022-07-01 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
WO2022143576A1 (zh) * | 2020-12-31 | 2022-07-07 | 恒元生物医药科技(苏州)有限公司 | 一种吡唑并喹唑啉类化合物、其制备方法及应用 |
JP2024505714A (ja) * | 2021-02-08 | 2024-02-07 | メッドシャイン ディスカバリー インコーポレイテッド | 5,6-ジドヒロチエノ[3,4-h]キナゾリン系化合物 |
CN113527310B (zh) * | 2021-07-30 | 2022-09-23 | 上海市肺科医院 | 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用 |
WO2023104178A1 (zh) * | 2021-12-10 | 2023-06-15 | 山东绿叶制药有限公司 | 蛋白激酶抑制剂及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2119975A (en) * | 1936-08-26 | 1938-06-07 | Beatrice S Nazel | Fluid pressure hammer |
JP3907220B2 (ja) * | 1994-06-30 | 2007-04-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 複素環含有化合物 |
CA2223081C (en) | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
IL147923A0 (en) | 1999-08-12 | 2002-08-14 | Pharmacia Italia Spa | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
CN102060857A (zh) | 2000-08-10 | 2011-05-18 | 辉瑞意大利有限公司 | 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物 |
US6489328B2 (en) * | 2000-08-11 | 2002-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
WO2002048114A1 (en) | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
WO2002070515A2 (en) | 2001-01-26 | 2002-09-12 | Pharmacia Italia Spa | Chromane derivatives, process for their preparation and their use as antitumor agents |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
EP1414522A2 (en) * | 2001-08-10 | 2004-05-06 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
EP1820503B1 (en) | 2001-09-26 | 2012-02-22 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
BR0307796A (pt) * | 2002-02-19 | 2004-12-21 | Pharmacia Corp | Derivados tricìclicos de pirazol para o tratamento de inflamação |
ES2436524T3 (es) * | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
JP5498796B2 (ja) * | 2006-12-21 | 2014-05-21 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ピラゾロ−キナゾリン誘導体、これらの調製方法及びキナーゼ阻害剤としてのこれらの使用 |
-
2004
- 2004-04-27 ES ES04741483.4T patent/ES2436524T3/es not_active Expired - Lifetime
- 2004-04-27 KR KR1020057022355A patent/KR101084871B1/ko active IP Right Grant
- 2004-04-27 PT PT47414834T patent/PT1636236E/pt unknown
- 2004-04-27 PL PL04741483T patent/PL1636236T3/pl unknown
- 2004-04-27 RS YUP-2005/0944A patent/RS20050944A/sr unknown
- 2004-04-27 US US10/557,565 patent/US7482354B2/en not_active Expired - Lifetime
- 2004-04-27 ME MEP-2008-259A patent/ME00142B/me unknown
- 2004-04-27 EP EP04741483.4A patent/EP1636236B1/en not_active Expired - Lifetime
- 2004-04-27 WO PCT/EP2004/050612 patent/WO2004104007A1/en active Application Filing
- 2004-04-27 NZ NZ543661A patent/NZ543661A/xx unknown
- 2004-04-27 CN CN2010105863199A patent/CN102079746A/zh active Pending
- 2004-04-27 MX MXPA05012573A patent/MXPA05012573A/es active IP Right Grant
- 2004-04-27 EA EA200501849A patent/EA010904B1/ru unknown
- 2004-04-27 JP JP2006530168A patent/JP5043432B2/ja not_active Expired - Lifetime
- 2004-04-27 UA UAA200512347A patent/UA80763C2/uk unknown
- 2004-04-27 OA OA1200500329A patent/OA13170A/fr unknown
- 2004-04-27 AP AP2005003452A patent/AP2064A/xx active
- 2004-04-27 DK DK04741483.4T patent/DK1636236T3/da active
- 2004-04-27 GE GEAP20049128A patent/GEP20094664B/en unknown
- 2004-04-27 AU AU2004240772A patent/AU2004240772B2/en not_active Expired
- 2004-04-27 RS RS20050944A patent/RS52899B/en unknown
- 2004-04-27 BR BRPI0410563A patent/BRPI0410563B8/pt active IP Right Grant
- 2004-04-27 CA CA2526578A patent/CA2526578C/en not_active Expired - Lifetime
- 2004-04-27 CN CNA2004800210752A patent/CN1826343A/zh active Pending
- 2004-04-27 SI SI200432118T patent/SI1636236T1/sl unknown
- 2004-04-27 BR BR122019010200A patent/BR122019010200B8/pt active IP Right Grant
- 2004-05-04 TW TW093112449A patent/TWI349672B/zh active
- 2004-05-13 MY MYPI20041795A patent/MY142019A/en unknown
- 2004-05-20 AR ARP040101748A patent/AR044543A1/es active IP Right Grant
-
2005
- 2005-11-18 IS IS8132A patent/IS2939B/is unknown
- 2005-11-20 IL IL172046A patent/IL172046A/he active IP Right Grant
- 2005-11-21 NO NO20055496A patent/NO334992B1/no unknown
- 2005-11-21 TN TNP2005000298A patent/TNSN05298A1/fr unknown
- 2005-11-21 HR HRP20050967AA patent/HRP20050967B8/hr not_active IP Right Cessation
- 2005-11-22 CR CR8102A patent/CR8102A/es unknown
- 2005-11-22 CO CO05118410A patent/CO5721006A2/es active IP Right Grant
- 2005-11-23 ZA ZA200509486A patent/ZA200509486B/xx unknown
- 2005-11-30 EC EC2005006194A patent/ECSP056194A/es unknown
-
2008
- 2008-10-31 US US12/262,933 patent/US8541429B2/en active Active
-
2013
- 2013-08-21 US US13/972,659 patent/US8981089B2/en active Active
- 2013-12-09 CY CY20131101108T patent/CY1114708T1/el unknown
-
2015
- 2015-02-18 US US14/625,093 patent/US9464090B2/en not_active Expired - Lifetime
- 2015-11-20 AR ARP150103780A patent/AR102722A2/es unknown
-
2016
- 2016-09-06 US US15/256,916 patent/US9637497B2/en not_active Expired - Lifetime
-
2017
- 2017-03-23 US US15/467,323 patent/US10280176B2/en not_active Expired - Lifetime
-
2019
- 2019-03-04 US US16/291,323 patent/US20190194214A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/084,862 patent/US20210300935A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA13170A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. | |
KR101223826B1 (ko) | 키나제 억제제로서의 치환된 피롤로-피라졸 유도체 | |
JP6181862B2 (ja) | ピラゾロピロリジン誘導体および疾患の処置におけるその使用 | |
JP2005529850A (ja) | 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用 | |
KR20150041787A (ko) | 2,3-벤조디아제핀 | |
EA028175B1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
WO2007071621A1 (en) | Heteroarylpyrrolopyridinones active as kinase inhibitors |